Employers
Ultragenyx Pharmaceutical, the Novato, Calif., rare-disease drugmaker, is cutting about 20% of its employees, according to a Form 8-K the company filed with the Securities and Exchange Commission on Tuesday, Nov. 3. The company said it told employees about the reduction the same day and expects it to be substantially completed by the end of 2026.
In its third-quarter earnings release, filed as an exhibit to the 8-K, Ultragenyx said the cut will leave it with a revised workforce of approximately 1,000 employees. The company did not say in the filing or the release how many people are losing their jobs, which sites or functions are affected, or whether any state layoff notices will be filed.
What the filing says
Under Item 2.05, the section of an 8-K used to disclose costs tied to exit or disposal activities, Ultragenyx estimated about $25 million in total restructuring and restructuring-related charges. It said those charges consist primarily of employee severance payments and other employee-related costs, and that it expects to recognize substantially all of them in the fourth quarter of 2026, with cash payments generally made over the same period. The filing cautions that the workforce reduction “may be greater or less than anticipated.”
The company’s quarterly report on Form 10-Q, filed Wednesday, Nov. 4, adds that the board of directors approved the restructuring plan in October 2026.
Why the company is cutting
Ultragenyx framed the move as a shift from late-stage drug development to selling products. The Food and Drug Administration approved two of its gene therapies in the third quarter: GENGLYCOS, for glycogen storage disease type Ia, and FAYUVI, for Sanfilippo syndrome type A. The company said it is “entering a new stage focused on commercial execution and a smaller, more targeted R&D footprint.”
Besides the headcount reduction, the plan includes completing the wind-down of all ongoing studies of GTX-102 for Angelman syndrome, ending the UX701 program for Wilson disease after it did not meet study goals, and cutting costs across the company, including shrinking its real estate footprint. Ultragenyx said it expects 2027 research and development spending of less than $350 million, which it described as at least a 50% reduction from 2025, and selling, general and administrative expenses of less than $375 million.
“With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward,” Chief Executive Emil Kakkis said in the release.
The financial backdrop
Ultragenyx reported third-quarter revenue of $173 million and a net loss of $118 million. It had $401 million in cash, cash equivalents and marketable securities as of Sept. 30, down from $737 million at the end of 2025. In October it agreed to sell the two priority review vouchers it received with the FDA approvals for a combined $413 million and expects net proceeds of about $350 million. The 8-K says the first voucher sale closed Oct. 30 for gross proceeds of $210 million, 20% of which goes to the National Institutes of Health under a patent license.
Second cut of 2026
This is the company’s second workforce reduction this year. According to the 10-Q, Ultragenyx carried out a restructuring in February 2026 that cut its workforce by approximately 10% and curtailed some operations, including manufacturing work for its osteogenesis imperfecta candidate UX143. That plan cost $30 million, of which $8 million was employee-related and $22 million was manufacturing-related, and the company said those payments were completed in the first half of the year.
For affected workers, the filings give few details beyond the overall severance estimate. The company has not disclosed individual severance terms, and it said the size, timing and cost of the reduction are estimates that could change. The filings do not break the reduction down by department or location. Employees and job seekers tracking the company should watch for state layoff notices, which are required for many larger reductions at a single site.
Sources
- Ultragenyx Pharmaceutical Inc., “Form 8-K, Current Report” (Items 2.01, 2.02, 2.05, 9.01), November 3, 2026. https://www.sec.gov/Archives/edgar/data/1515673/000119312526445342/rare-20261030.htm
- Ultragenyx Pharmaceutical Inc., “Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027,” November 3, 2026. https://www.sec.gov/Archives/edgar/data/1515673/000119312526445342/rare-ex99_1.htm
- Ultragenyx Pharmaceutical Inc., “Form 10-Q, Quarterly Report for the period ended September 30, 2026,” November 4, 2026. https://www.sec.gov/Archives/edgar/data/1515673/000119312526445718/rare-20260930.htm
Featured photo: A pre-PCR setup area at the Viral and Human Genomics Lab of the UASLP Faculty of Medicine in San Luis Potosí, Mexico, Oct. 27, 2016. Representative image; not Ultragenyx or its facilities. Photo: Ca.garcia.s, via Wikimedia Commons (CC BY-SA 4.0). Cropped from the original.
